Vivo Capital, fresh off raising $750 million for its eight fund, has effectively strad-dled the Pacific, investing in life sciences in US and China. Managing Partner Chen Yu, MD, shares Vivo’s story and explains how US Medtech start-ups stand to benefit from China’s soar-ing health care sector.
